Diamyd Medical (former Diamyd Therapeutics) is a diabetes company headquartered in Stockholm, Sweden. The Company develops the diabetes vaccine Diamyd®and the active ingredient GAD for the treatment and prevention of autoimmune diabetes. Two Swedish researcher-initiated Phase II studies with Diamyd®are ongoing. One study evaluates whether the diabetes vaccine can prevent type 1 diabetes in children who are at high risk of developing the disease and one study evaluates whether Diamyd®in combination with relatively high doses of vitamin D and ibuprofen can preserve the body's own ability to control the blood sugar level in children and adolescents newly diagnosed with type 1 diabetes. Diamyd Medical also has holdings in the gene therapy company Periphagen Holdings, Inc. (US).